Why Some Spider Veins Resist Microsclerotherapy: The Role of Vessel Size and When to Change Your Approach

By Dr. Haroun Gajraj | VeinCare Academy | 17th June 2026

This review is written for healthcare professionals who perform microsclerotherapy for leg telangiectasia and reticular veins. It examines why some C1 lesions fail to clear with standard injection technique, how vessel diameter determines treatment response, and what the current published evidence supports in terms of modality selection and clinical decision-making when standard approaches are not working. I offer both microsclerotherapy and 4 MHz radiofrequency thermocoagulation in my own practice, and the framework described here reflects how I approach treatment-resistant cases.

A note on sources: Duffy's original classification text has not been independently verified on PubMed and is therefore not cited directly in this article. The clinical framework it introduced is, however, well supported by subsequent PubMed-indexed trials and studies, which form the evidence base used here.

🎥 Prefer video? Watch the full review on YouTube: "Why Some Spider Veins Resist Microsclerotherapy: The Role of Vessel Size and When to Change Approach)" [→click here]

Contents

1. Introduction: when microsclerotherapy does not work

2. Why treatment resistance is often not a technique problem

3. The core logic of size-based classification

4. What the evidence shows: treatment response by vessel diameter

5. Responsive and resistant telangiectasia: a practical framework

6. The role of 4 MHz thermocoagulation

7. Using needle gauge as a bedside size comparator

8. Implications for duplex ultrasound screening policy

9. Key clinical points

10. References

1. Introduction: When Microsclerotherapy Does Not Work for Leg Telangiectasias and Reticular Vein (spider veins and blue veins

Most courses of microsclerotherapy for leg telangiectasia produce satisfactory results. The vessels blanch on injection, the treated area fades over the following weeks, and the patient is pleased.

But some do not. A proportion of lesions resist repeated treatment. They are injected carefully, at appropriate concentrations, by practitioners with sound technique — and they persist. Or they clear partially, only to return in the same distribution within a few months. Or they simply fail to respond from the outset, despite seemingly correct injection.

When this happens, the instinctive response is often to question the technique: was the needle correctly placed? Was the concentration sufficient? Was the compression adequate?

These are reasonable questions. But in many cases, the answer lies not in the technique at all. It lies in the vessel itself — specifically, in its size.

This article examines the evidence for vessel diameter as the primary determinant of treatment response within CEAP C1 disease, explains why the smallest telangiectasia form a clinically distinct subgroup that behaves differently under injection, and sets out a practical framework for changing approach when standard microsclerotherapy is not working.

2. Why Treatment Resistance Is Often Not a Technique Problem

Microsclerotherapy is performed across a range of vessel diameters that are all grouped under the single CEAP label of C1. That label covers telangiectasias — vessels under 1 mm — and reticular veins from 1 to 3 mm. In everyday clinical use, this range is frequently treated as a single category, with the same basic approach applied regardless of the calibre of the vessel being injected [4][5].

The clinical consequence is predictable. A patient with fine red thread veins at 0.2 mm and a patient with prominent blue reticular feeders at 2.5 mm will both receive a microsclerotherapy session. For the larger vessels, the results are generally good. For the finer ones, they may not be — and when they are not, there is often no clear explanation in the C1 label itself for why.

Without a finer size-based framework, clinicians lack the language to distinguish a lesion that is straightforwardly injectable from one that is biologically and technically resistant to injection. And without that distinction, the natural tendency is to repeat the same approach, at the same or slightly higher concentration, without a change in strategy.

A size-based framework — consistent with the classification that Duffy introduced — provides that language. It makes vessel diameter the central organising principle within C1 disease, and it aligns diameter with three practical decisions: which modality to use, what outcome to expect, and when to investigate further [3][4].

3. The Core Logic of a Size-Based Classification

The key insight of a size-based classification is that very small intradermal telangiectasias — those at or below approximately 0.2 to 0.3 mm — have biological characteristics that make them poorly suited to injection, regardless of the sclerosant used or the technique employed.

These vessels have very low luminal volume and thin walls. Their capacity to accept sclerosant without extravasation or a disproportionate inflammatory response is limited. They are technically difficult to cannulate with any needle, including a 30-gauge. And even when injection appears technically successful, the sclerosant contact time and endothelial exposure may be insufficient to produce reliable fibrosis and vessel obliteration.

At the other end of the C1 spectrum, reticular feeders from 1 to 3 mm have greater luminal volume, are more accessible to injection, and respond well to liquid sclerotherapy when appropriate concentrations are used. Their resistance, when it occurs, tends to be haemodynamic — driven by reflux from a proximal or perforating source — rather than related to vessel calibre alone.

Between these two ends of the spectrum lies a clinically important middle ground where injection is often feasible, but where outcome depends on careful assessment of the individual lesion's size, pattern, and haemodynamic context.

The practical question for every resistant case is: which of these categories does this vessel belong to, and does that change what I should do next?

4. What the Evidence Shows: Treatment Response by Vessel Diameter

The strongest direct evidence that vessel size changes treatment performance within C1 disease comes from a prospective randomised study by Trelles et al. (2020) involving 285 women and 570 legs treated across pairwise comparisons [1].

For telangiectasias under 1 mm in diameter, long-pulsed Nd:YAG laser was superior to sclerotherapy. As diameter increased within the C1 range, polidocanol became more effective relative to laser. This is not a marginal finding — it means that the choice of modality should be informed by vessel size, and that applying injection to the finest vessels is not simply a less-than-ideal choice but may be the wrong choice for that size band.

A blinded comparative trial by McCoy, Evans, and Spurrier (1999) reinforced the same principle from a different angle, showing that outcomes for small leg telangiectasia depend on the method used and the vein phenotype, with different adverse sequelae profiles even when overall efficacy is comparable [7]. Vessel type and size interact with treatment choice in ways that a single C1 label does not capture.

Goldman's narrative review (2006) described light and laser modalities as particularly effective for vessels up to 1 mm, consistent with the idea that the smallest size band has characteristics that favour non-injection approaches [8].

Taken together, these studies point to the same conclusion: within C1 disease, the 1 mm threshold is a meaningful dividing line. Below it, injection becomes progressively less reliable as vessel calibre decreases. Above it, sclerotherapy with polidocanol is the primary modality and is well supported by the evidence.

When a practitioner encounters a cluster of fine telangiectasias that have not responded to repeated injection, the Trelles data suggest a plausible explanation: the vessels may simply be too fine for sclerotherapy to work reliably, regardless of technical quality.

5. Responsive and Resistant Telangiectasia: A Practical Framework

The distinction between responsive and resistant telangiectasia is the most clinically useful concept that a size-based classification makes possible. It is not yet standardised guideline terminology, but it has a clear basis in the evidence and a direct bearing on how to manage cases that are not responding.

A responsive lesion is one whose size, isolation, and lack of feeder reflux make it likely to clear with standard microsclerotherapy or direct thermal treatment. A resistant lesion is one that is extremely fine, densely clustered, rapidly refilling, recurrent, or haemodynamically connected to a refluxing feeder — characteristics that make single-technique injection less likely to succeed.

Ferrara and Ferrara (2013) operationalised this distinction formally in a prospective clinical trial of 63 patients and 125 limbs, proposing a pathophysiological subclassification with three types [3]:

- Type A: reflux-associated lesions, where the haemodynamic source must be addressed before or alongside surface treatment.

- Type B: clustered spider telangiectasias greater than 0.2 mm not related to underlying reflux.

- Type C: isolated telangiectatic veins of 0.2 mm or less, which behave as a clinically distinct subgroup requiring a different treatment approach.

The Ferrara study reported better 12-month aesthetic and functional results with a multitherapy protocol aligned to this subclassification than with a standard sclerotherapy approach. The evidence grade is lower than a conventional superiority RCT, but the clinical contribution is significant: it formalises the idea that some telangiectasias are resistant not because of operator technique, but because very small calibre and lesion architecture change the biological response to injection.

This reframing is important in practice. When a patient returns after a second or third course of treatment with persistent fine vessels, it is worth asking whether those vessels are Type C lesions — too small to inject reliably — rather than continuing with the same approach at a higher concentration.

For Type A lesions — those with visible recurrence in the same distribution, rapidly refilling vessels, or dense clustered patterns — the question is different. Here the resistance may be haemodynamic: an untreated reticular feeder or perforating vessel supplying the surface telangiectasia. In these cases, a change of modality alone is unlikely to resolve the problem, and investigation is warranted.

6. The Role of 4 MHz Thermocoagulation

For Type C lesions — isolated, ultra-fine telangiectasias at or below approximately 0.2 to 0.3 mm — radiofrequency thermocoagulation at 4 MHz is the modality most suited to the clinical problem.

Thermocoagulation uses a fine insulated needle to deliver high-frequency energy directly to a small vessel, producing thermal endothelial destruction without requiring intraluminal injection. Because the needle does not need to enter the vessel lumen, the limitations that make very fine vessels resistant to sclerotherapy — low luminal volume, difficult cannulation, inadequate sclerosant contact — do not apply.

In my practice, I use thermocoagulation selectively alongside microsclerotherapy rather than as a replacement for it. The two modalities address different parts of the size spectrum, and combining them where appropriate gives a more complete response than either technique alone. In a typical session, I begin with thermocoagulation for the finest visible vessels and then proceed with injection for the larger telangiectasias and reticular feeders.

The best trial evidence for this approach comes from a randomised controlled pilot study by Diken et al. (2021) of 111 patients with CEAP C1 spider veins, which showed that adjuvant RF thermocoagulation added to liquid sclerotherapy improved self-assessed cosmetic outcomes and reduced both hyperpigmentation and trapped blood compared with sclerotherapy alone, without any increase in necrosis risk [2]. This matches my own clinical experience: the benefit is most apparent for vessels that are too fine to cannulate reliably, or that have responded incompletely to injection in a previous session.

I want to be clear about where the evidence sits: this was a pilot study, not a large definitive RCT. But it is randomised evidence for a real clinical benefit, and it supports the selective use of thermocoagulation in precisely the size band where injection is least reliable.

For cases where repeated microsclerotherapy has produced incomplete clearance of very fine vessels, a trial of thermocoagulation is a clinically reasonable next step before concluding that the vessels are untreatable.

7. Using Needle Gauge as a Bedside Size Comparator

When assessing a resistant case and considering whether to change modality, a practical first question is whether the vessel is actually within the injectable size range.

A 30-gauge needle has an outer diameter of approximately 0.30 to 0.31 mm. No PubMed study has formally validated needle gauge as a measurement standard for telangiectasia diameter, and it should be understood as a practical visual comparator rather than a validated morphometric tool.

The clinical inference is nonetheless useful. If a persistent or resistant telangiectasia appears clearly narrower than the outer diameter of a 30G needle, it is likely at or below 0.3 mm — in the size band where thermocoagulation or laser is more likely to succeed than repeated injection. If it is equal to or wider than the 30G outer diameter, microsclerotherapy remains technically feasible, and the cause of resistance is more likely to be haemodynamic than calibre-related.

I use this comparison routinely when reviewing a patient who has had an incomplete response to previous treatment. It is also a useful tool for patient explanation: "These very fine vessels are narrower than the needle I would use to inject them, which is why I am going to use a different approach for them this time." That explanation is more precise than "these ones are difficult" and more honest about the reason for changing strategy.

8. Implications for Duplex Ultrasound Screening Policy

A size-based framework also has direct implications for how duplex ultrasound scanning (DUS) should be used when telangiectasia are not responding to treatment — and this connects to the selective DUS policy supported by the UIP (2024) and SVS/AVF/AVLS (2023), discussed in my earlier article on duplex before microsclerotherapy.

The key point is that the clinical features that identify a resistant lesion also determine whether a duplex scan is likely to change management.

DUS is not routinely required when:

- The resistant vessels are isolated, ultra-fine (at or below 0.2 to 0.3 mm), with no symptoms and no pattern suggesting haemodynamic involvement

- The clinical picture is consistent with Type C resistance — small calibre rather than reflux — in which case thermocoagulation or laser is the appropriate next step and scanning is unlikely to alter that decision

DUS should be performed when:

- Telangiectasia recur in the same distribution after apparently adequate treatment, suggesting an untreated feeder source

- There are dense clustered or rapidly refilling patterns, particularly in the thigh or popliteal area

- Coexisting reticular veins or visible tributary varicosities suggest a haemodynamic driving mechanism

- The patient reports symptoms consistent with venous disease: aching, heaviness, swelling, or skin changes

- There is a history of prior venous interventions or deep vein thrombosis [4][5]

Recurrence in the same distribution is one of the most clinically important triggers. If a patient has had careful, technically sound treatment and the same vessels return within a few months, that pattern strongly suggests a persistent haemodynamic source. Duplex will often clarify what it is.

A size and pattern framework adds specificity to the DUS decision: it helps distinguish Type C resistance — where scanning will not change the approach — from Type A resistance, where it is essential.

9. Key Clinical Points

- Treatment resistance in leg telangiectasia is often not a function of operator error. Vessel calibre and lesion architecture are frequently the determining factors.

- CEAP C1 groups telangiectasias and reticular veins into a category that is too broad to explain or predict treatment resistance [4][5].

- A size-based classification, consistent with the framework Duffy introduced, uses vessel diameter as the primary bedside discriminator within C1 disease.

- Randomised evidence shows that vessels under 1 mm respond differently from larger C1 lesions: Nd:YAG laser outperforms injection at the fine end, while polidocanol becomes progressively more effective as diameter increases [1].

- The Ferrara subclassification (2013) formalises the distinction between reflux-associated resistance (Type A), clustered non-reflux lesions (Type B), and ultra-fine isolated lesions that are biologically resistant to injection (Type C) [3].

- For Type C lesions at or below 0.2 to 0.3 mm, 4 MHz radiofrequency thermocoagulation is the modality most likely to succeed where injection has not [2][3].

- The outer diameter of a 30G needle (approximately 0.30 mm) provides a practical visual comparator for identifying vessels that are likely too fine to inject reliably, though it is not a validated measurement standard.

- Recurrence in the same distribution after adequate treatment is a strong indication of an untreated haemodynamic source and a clear trigger for duplex ultrasound scanning [4][5].

- DUS is not routinely required for isolated ultra-fine resistant lesions where the resistance is clearly calibre-related; it is essential when recurrence or the clinical pattern suggests reflux.

- When standard microsclerotherapy is not working, the first question should be: is this a size problem, a haemodynamic problem, or both?

10. References *

1. Trelles MA, Allones I, Moreno-Arias G, Vélez M. Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. J Cosmet Laser Ther. 2020;22(3):131–137. PMID: 30679981. https://pubmed.ncbi.nlm.nih.gov/30679981/

2. Diken AI, Alemdaroglu U, Özyalçin S, Hafez I, Tünel HA, Yalçinkaya A, Ecevit AN. Adjuvant radiofrequency thermocoagulation improves the outcome of liquid sclerotherapy in the treatment of spider veins of the leg: a pilot study. Phlebology. 2021;36(8):620–626. PMID: 33813962. https://pubmed.ncbi.nlm.nih.gov/33813962/

3. Ferrara F, Ferrara G. Treating telangiectasias: my method. Minerva Cardioangiol. 2013;61(2):221–227. PMID: 23492605. https://pubmed.ncbi.nlm.nih.gov/23492605/

4. De Maeseneer MG, Kakkos SK, Aherne T, et al. European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. PMID: 35027279. https://pubmed.ncbi.nlm.nih.gov/35027279/

5. Gloviczki P, Lawrence PF, Wasan SM, et al. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101670. PMID: 37652254. https://pubmed.ncbi.nlm.nih.gov/37652254/

6. Nakano LCU, Cacione DG, Baptista-Silva JC, Flumignan RLG. Treatment for telangiectasias and reticular veins. Cochrane Database Syst Rev. 2021;10(10):CD012723. PMID: 34637138. https://pubmed.ncbi.nlm.nih.gov/34637138/

7. McCoy S, Evans A, Spurrier N. Sclerotherapy for leg telangiectasia: a blinded comparative trial of polidocanol and hypertonic saline. Dermatol Surg. 1999;25(5):381–386. PMID: 10469077. https://pubmed.ncbi.nlm.nih.gov/10469077/

8. Neumann HA, Kockaert MA. The treatment of leg telangiectasia. J Cosmet Dermatol. 2003 Apr;2(2):73-81. . PMID: 17156060.

https://pubmed.ncbi.nlm.nih.gov/17156060/

---

About the Author

This educational article is written and regularly reviewed by Dr Haroun Gajraj, a GMC-registered vein specialist who has treated thousands of patients with vein disease and has trained many doctors and nurses in microsclerotherapy, shortwave diathermy and related cosmetic vein procedures. Dr Gajraj is the founder and board member of the British Association of Sclerotherapists.

You can view his current GMC registration and independent patient reviews on iWantGreatCare for further information about his clinical background. It is designed for healthcare professionals and is based on current clinical guidelines, peer-reviewed research and day-to-day practice experience. The information here is general education only and is not a substitute for individual clinical judgement, local protocols or formal training. Clinicians remain responsible for assessing each patient, obtaining informed consent, explaining risks and alternatives, and working within the scope of their professional registration and regulatory guidance.

Subscribe

For regular updates get my weekly newsletter here

© VeinCare Academy | Dr. Haroun Gajraj | veincare.academy
This article is intended for qualified healthcare professionals. All clinical decisions should be based on individual patient assessment, primary medical literature and current professional guidelines.

*All references in this blog have been checked against publicly available sources (for example, PubMed and official guideline websites), but this is an educational blog post, not a peer-reviewed journal article. Minor discrepancies in author lists, page numbers or indexing details may remain, and readers should always refer to the original publications and current clinical guidelines before making clinical decisions.